Stem cell therapy of myocardial infarction: a promising opportunity in bioengineering.

Autor: Jiang B; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States., Yan L; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States., Shamul JG; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States., Hakun M; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States., He X; Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States.
Jazyk: angličtina
Zdroj: Advanced therapeutics [Adv Ther (Weinh)] 2020 Mar; Vol. 3 (3). Date of Electronic Publication: 2020 Feb 03.
DOI: 10.1002/adtp.201900182
Abstrakt: Myocardial infarction (MI) is a life-threatening disease resulting from irreversible death of cardiomyocytes (CMs) and weakening of the heart blood-pumping function. Stem cell-based therapies have been studied for MI treatment over the last two decades with promising outcome. In this review, we critically summarize the past work in this field to elucidate the advantages and disadvantages of treating MI using pluripotent stem cells (PSCs) including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), adult stem cells, and cardiac progenitor cells. The main advantage of the latter is their cytokine production capability to modulate immune responses and control the progression of healing. However, human adult stem cells have very limited (if not 'no') capacity to differentiate into functional CMs in vitro or in vivo. In contrast, PSCs can be differentiated into functional CMs although the protocols for the cardiac differentiation of PSCs are mainly for adherent cells under 2D culture. Derivation of PSC-CMs in 3D, allowing for large-scale production of CMs via modulation of the Wnt/β-catenin signal pathway with defined chemicals and medium, may be desired for clinical translation. Furthermore, the technology of purification and maturation of the PSC-CMs may need further improvements to eliminate teratoma formation after in vivo implantation of the PSC-CMs for treating MI. In addition, in vitro derived PSC-CMs may have mechanical and electrical mismatch with the patient's cardiac tissue, which causes arrhythmia. This supports the use of PSC-derived cells committed to cardiac lineage without beating for implantation to treat MI. In this case, the PSC derived cells may utilize the mechanical, electrical, and chemical cues in the heart to further differentiate into mature/functional CMs in situ. Another major challenge facing stem cell therapy of MI is the low retention/survival of stem cells or their derivatives (e.g., PSC-CMs) in the heart for MI treatment after injection in vivo. This may be resolved by using biomaterials to engineer stem cells for reduced immunogenicity, immobilization of the cells in the heart, and increased integration with the host cardiac tissue. Biomaterials have also been applied in the derivation of CMs in vitro to increase the efficiency and maturation of differentiation. Collectively, a lot has been learned from the past failure of simply injecting intact stem cells or their derivatives in vivo for treating MI, and bioengineering stem cells with biomaterials is expected to be a valuable strategy for advancing stem cell therapy towards its widespread application for treating MI in the clinic.
Competing Interests: Conflict of Interest The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz: